A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

Recurrent C. diff infections linked to higher death rates, research shows Clostridium difficile infection recurrence may increase the risk of death in patients, according to a presentation at the 27th ...

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff ...

Please provide your email address to receive an email when new articles are posted on . Rebyota was effective in real-world analyses, with results consistent with the PUNCH CD3 trial. Rebyota was also ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

Please provide your email address to receive an email when new articles are posted on . Treatment-emergent adverse events occurred in 66.4% of patients who received Rebyota vs. 60.2% on placebo. Most ...

A study published in JAMA Internal Medicine found patients receiving gastric acid suppressants may be at an increased risk for recurrent Clostridium difficile infections. Rochester, Minn.-based Mayo ...

New research, from Philadelphia-based University of Pennsylvania, claims multiple recurrent Clostridium difficile infection rates have rapidly increased. University of Pennsylvania postdoctoral fellow ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA @ Home ...

The case could represent the first known instance of cat-to-human transmission of recurrent C. diff, though more research is needed to confirm this risk. Reading time 3 minutes A woman’s newly adopted ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...